[
  {
    "ts": "2025-09-02T12:00:00+00:00",
    "headline": "Agilent’s MMR IHC Panel pharmDx (Dako Omnis) Receives European IVDR Certification as a Companion Diagnostic Test for Colorectal Cancer",
    "summary": "SANTA CLARA, Calif., September 02, 2025--Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer. MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify mismatch repair (MMR) deficient CRC patients eligible for treatment with OPDIVO® (nivolumab) in combination with YERVOY® (ipilimumab). MMR IHC Pan",
    "url": "https://finance.yahoo.com/news/agilent-mmr-ihc-panel-pharmdx-120000323.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "6acd21e0-f73b-3bad-95c8-e8665490c71e",
      "content": {
        "id": "6acd21e0-f73b-3bad-95c8-e8665490c71e",
        "contentType": "STORY",
        "title": "Agilent’s MMR IHC Panel pharmDx (Dako Omnis) Receives European IVDR Certification as a Companion Diagnostic Test for Colorectal Cancer",
        "description": "",
        "summary": "SANTA CLARA, Calif., September 02, 2025--Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer. MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify mismatch repair (MMR) deficient CRC patients eligible for treatment with OPDIVO® (nivolumab) in combination with YERVOY® (ipilimumab). MMR IHC Pan",
        "pubDate": "2025-09-02T12:00:00Z",
        "displayTime": "2025-09-02T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/7827e6b4b9547c39c3c17ad7343d7e46",
          "originalWidth": 1000,
          "originalHeight": 404,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1YX6MEL2.4Xnerv714N2zA--~B/aD00MDQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/7827e6b4b9547c39c3c17ad7343d7e46.cf.webp",
              "width": 1000,
              "height": 404,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mCH4dNpl9BYJzUqjKj.yXg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7827e6b4b9547c39c3c17ad7343d7e46.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/agilent-mmr-ihc-panel-pharmdx-120000323.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/agilent-mmr-ihc-panel-pharmdx-120000323.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "A"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]